Thompson v. Western States Medical Center
The Supreme Court struck down federal rules that let pharmacies skip FDA drug-approval testing for custom-mixed "compounded" drugs only if they promised not to advertise those specific drugs, ruling the advertising ban violated the pharmacies' free speech rights.
The decision means the government cannot use a ban on truthful advertising as its tool for separating small-scale pharmacy compounding from large-scale drug manufacturing, forcing regulators to find other ways to draw that line if they want to keep it in place.
“If the First Amendment means anything, it means that regulating speech must be a last — not first — resort.”
The Court's central rationale for striking down the advertising ban.
How it got here: A federal trial court and the Ninth Circuit both found the advertising restrictions unconstitutional; the government's appeal to the Supreme Court raised only that constitutional question.
The Case in Depth
What happened
Compounding pharmacies mix custom medications for patients with special needs, such as drug allergies, that mass-produced drugs can't meet. A 1997 federal law let compounded drugs skip the FDA's standard drug-approval process, but only if the pharmacy avoided advertising or promoting specific compounded drugs. A group of compounding pharmacies that distributed promotional materials about their products sued, fearing prosecution, and argued the advertising restriction violated their free-speech rights.
The question before the Court
Can the government require specialty pharmacies to stop advertising specific compounded drugs as the price for skipping normal FDA drug-approval testing?
The Court's answer
No — the Court ruled that conditioning a pharmacy's exemption from FDA drug-approval testing on a promise not to advertise specific compounded drugs violates the First Amendment. The government's interest in separating small-scale compounding from large-scale drug manufacturing was legitimate, but banning truthful advertising was not a permissible way to draw that line.
The Court found the government hadn't shown the speech restriction was necessary — several non-speech alternatives, like limiting equipment, batch sizes, or sales volume, could achieve the same goal without silencing pharmacists. Because the ban also blocked plenty of useful, non-misleading information to patients and doctors, it went further than the First Amendment allows.
Curious how the Court got there? See the step-by-step legal reasoning →
Why it matters
Compounding pharmacies can now advertise and promote specific custom-mixed drugs to patients and doctors without losing their exemption from costly FDA approval testing. Patients with unique medical needs — like drug allergies or trouble swallowing pills — may get better information about specialized treatment options, though the ruling leaves Congress needing a new approach if it wants to limit large-scale compounding.
What changes now
This is a final merits decision resolving the constitutional question. Because neither side had sought review of the lower court's separate ruling that the advertising restrictions could not be severed from the rest of the compounding exemption, that portion of the Ninth Circuit's judgment stands undisturbed, meaning the entire compounding provision, not just the advertising ban, remains invalidated unless Congress rewrites the law.
What this does not decide
The Court did not review or disturb the Ninth Circuit's separate ruling that the speech restrictions could not be severed from the rest of the compounding exemption, since neither party asked the Court to review that issue. The decision also does not address restrictions on advertising directed specifically at physicians rather than consumers.
Concurrences and dissents
Concurrence — Justice Thomas
Justice Thomas agreed with how the majority applied the Central Hudson test but reiterated his broader view that commercial speech restrictions like this one should not be analyzed under Central Hudson at all, especially when the government's goal is to keep people uninformed.
Dissent — Justice Breyer
“I do not believe that Congress could have achieved its safety objectives in significantly less restrictive ways.”Breyer's disagreement with the majority's less-restrictive-alternatives analysis.
Justice Breyer argued the majority undervalued the government's safety interest, contending the advertising ban directly advanced a second goal the majority ignored: ensuring compounded drugs go to patients with genuine medical need rather than those merely seeking convenience. He argued the proposed alternatives wouldn't address that need-based concern and would have upheld the restriction as applied to consumer advertising.
How the Court got there
The legal reasoning, step by step
- The Court applied the four-part Central Hudson test for commercial speech, which asks whether the speech is about lawful, non-misleading activity, whether the government's interest is substantial, whether the restriction directly advances that interest, and whether it is no more extensive than necessary.
- The government did not dispute that the advertising was lawful and non-misleading, and the Court accepted that preserving the integrity of the FDA's drug-approval process was a substantial government interest.
- Even assuming the advertising ban helped advance that interest by using advertising as a proxy for large-scale manufacturing, the Court found the government had not shown the restriction was no more extensive than necessary.
- The Court pointed to several non-speech alternatives — such as limiting equipment, batch sizes, wholesale sales, or out-of-state volume — that could achieve the same goal without restricting truthful speech, and found the government had not explained why these wouldn't work.
- The Court also relied on precedent holding that the government cannot restrict truthful commercial speech merely out of fear that people will use accurate information to make choices the government disfavors.
- Because banning the advertising of compounded drugs would also silence a substantial amount of useful, non-misleading speech serving no clear regulatory purpose, the Court concluded the restriction failed the final prong of the Central Hudson test.
Doctrinal impact
Cases affected by this decision
Reaffirms Central Hudson Gas & Elec. Corp. v. Public Serv. Comm'n of N. Y. (447 U. S. 557)
The Court applied this existing four-part test for regulating commercial speech rather than adopting a new standard.
Reaffirms Virginia Bd. of Pharmacy v. Virginia Citizens Consumer Council, Inc. (425 U. S. 748)
The Court relied on this case's rule that the government cannot ban truthful ads just to keep people from making 'bad' choices.